-
Mashup Score: 4Introduction to BloodCancerTalks - 2 day(s) ago
Transistor (https://transistor.fm) https://feeds.transistor.fm/bloodcancertalks This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharu
Source: feeds.transistor.fmCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 16
Podcast Episode · Blood Cancer Talks · 02/12/2025 · 1h 3m
Source: podcasts.apple.comCategories: General Medicine News, Partners & KOLsTweet-
Tune in to our new episode on management of CML with @DrHKantarjian! We discuss into the latest asciminib data and nuances of choosing the optimal TKI to use in 1st line! @AshKishtagari https://t.co/5riPdsA5mV https://t.co/G4ct0vUBxc
-
-
Mashup Score: 6Episode 55. ASH 2024 Myeloma Updates with Dr. Rakesh Popat | Blood Cancer Talks | Episode 56 - 3 month(s) ago
In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMMOverview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
Listen to our new episode on #ASH24 #MultipleMyeloma updates with @DrRakeshPopat! We discuss: AQUILA GMMG-HD7 iMMagine-1 CARTITUDE-4 MRD update ANDROMEDA OS update OPTIMUM-MUKnine update Check out this clip on Dr. Popat's take on anito-cel data! https://t.co/UCYvYo11ew https://t.co/lXT7NETnxs
-
-
Mashup Score: 2Episode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel | Blood Cancer Talks | Episode 39 - 3 month(s) ago
In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed:1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
@HangQuach1 @StVHealthAust @ADispenzieri 5. #ASH23 update on leukemia and myeloid malignancies with @Anand_88_Patel! We critically appraised TRANFORM-1, MANIFEST-2, AUGMENT-101, and many more trials! https://t.co/RIdfhUFxbP
-
-
Mashup Score: 39Episode 40. Management of Newly Diagnosed AL Amyloidosis | Blood Cancer Talks | Episode 41 - 3 month(s) ago
In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed:1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: …
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
Tune in to our new episode on management of AL Amyloidosis with @ADispenzieri! We dive into the nuances of management including tissue biopsy, risk stratification, monitoring patients while on Dara-VCD, and many more critical issues! https://t.co/qH9gsov1p5 Check out this clip: https://t.co/gnMRfBAu1s
-
-
Mashup Score: 3Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach | Blood Cancer Talks | Episode 54 - 3 month(s) ago
In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM….
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
3. The comeback of belantamab with @HangQuach1 @StVHealthAust! We had a wide-ranging discussion on DREAMM-7 and 8 RCTs, ocular toxicity of belantamab, and how will it fit into the current treatment paradigm! https://t.co/05A4bO4Gle
-
-
Mashup Score: 1Episode 51. Venetoclax in AML with Dr. Andrew Wei | Blood Cancer Talks | Episode 52 - 3 month(s) ago
In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa20129712. 10 day Decitabine plus venetoclax for ND AML…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
1. Venetoclax in AML with Andrew Wei @PeterMacCC ! We discussed the history of venetoclax development and practical tidbits on managing AML with venetoclax-based regimens! https://t.co/WFqqrYi2EP
-
-
Mashup Score: 42Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi | Blood Cancer Talks | Episode 43 - 3 month(s) ago
In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel):…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
Tune in to our new episode on CAR T-cell therapy in early relapsed #MultipleMyeloma with @HadidiSamer! We dissect the data presented at @FDAOncology ODAC and how to make sense of it in clinical practice as we anticipate approval soon! https://t.co/4kWqQPcFFo https://t.co/8aKWnLeG0m
-
-
Mashup Score: 22Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt | Blood Cancer Talks | Episode 51 - 8 month(s) ago
In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
Tune in to our new episode on quadruplets in newly diagnosed transplant-ineligible #Myeloma with @TMSchmidtMD! 🎙️ We break down the IMROZ & BENEFIT trials and how to apply them in our current practice. 🩺🔍 https://t.co/llyKn6PmpW Check out this short clip! https://t.co/GX8So3HWCe
-
-
Mashup Score: 18Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl | Blood Cancer Talks | Episode 50 - 8 month(s) ago
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial:…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
Tune in to our new episode on updates in low-risk MDS with @MaxStahlMD! We discuss the recent trials on imetelstat and luspatercept. https://t.co/UdR0MxY8Sn @AshKishtagari @Eddie_Cliff Here is a clip on imetelstat: https://t.co/8b80zThUF9
-
At @bloodcancertalks, we are committed to bringing fiercely independent and nuanced coverage of latest advances in hematologic malignancies in a "𝐇𝐨𝐰 𝐈 𝐓𝐫𝐞𝐚𝐭" format from thought leaders in the field! Check out our episodes➡️https://t.co/0QghqgcD9D! https://t.co/d8aj671oPK